bioAffinity Technologies Inc. (NASDAQ:BIAF) saw its stock climb to $2.96 during pre-market trading on Wednesday, marking a 20.82% jump from its previous close. The surge came after the company released its third-quarter sales update.
Check out the current price of BIAF stock here.
Third Quarter Sales Performance
The Texas-based company announced on Tuesday that sales of its CyPath® Lung diagnostic test reached a record high in the third quarter, marking a 95% increase from the previous quarter. For the first nine months of 2025, sales rose 97% compared to the same period last year.
Test Specifications
The test uses advanced technology to examine mucus from patients' lungs. Clinical studies have shown it achieves 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with lung nodules smaller than 20 millimeters.
See Also: Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight?
Market Expansion and Adoption
The increase reflects broader use of CyPath® Lung by Veterans’ hospitals and continued market growth in the mid-Atlantic region, the company said.
Third-quarter results also showed a 77% rise in new patients using CyPath® Lung, along with higher compliance in collecting and returning at-home samples.
Stock Performance
bioAffinity has dropped sharply over the past year, losing 95.33%, and has fallen 85.98% in the last six months. Its price has ranged between $2.34 and $67.12 during this time.
The biotech’s market capitalization stands at $7.11 million, with an average daily trading volume of 3.85 million shares.
Price Action: According to Benzinga Pro, BIAF closed Tuesday's regular trading session at $2.45, up 4.3%.
Benzinga Edge Stock Rankings indicate that bioAffinity Technologies has a negative price trend across all time frames. Track the performance of other players in this segment.
Read Next:
- What’s Behind AlphaTON Capital’s 123% After-Hours Spike?
Photo courtesy: jira pliankharom on Shutterstock.com
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.